Addition Of Azithromycin To Daily Trimethoprim-Sulfamethoxazole Treatment Does Not Reduce Malaria, STI Risk Among Pregnant Women With HIV At Delivery, Study Finds

Healio (5/16, Stulpin) reports, “The addition of azithromycin to daily trimethoprim-sulfamethoxazole treatment among pregnant women with HIV did not reduce the rate of malaria or bacterial sexually transmitted infections at delivery, data show.” In the study, published in Open Forum Infectious Diseases, researchers “reported no difference in the proportion of women with malaria (16.3% in TMP-SMX-azithromycin vs. 13.2% in TMP-SMX-placebo; relative risk [RR] = 1.24; 95% CI, 0.71-2.16) or STI (4.2% in TMP-SMX-azithromycin vs. 5.8% in TMP-SMX-placebo; RR = 0.72; 95% CI, 0.26-2.03) at delivery.”